Conventional, established medicine for its cleared indications — a real pressure-and-oxygen mechanism. The anchor that makes the evidence gradient legible; routinely over-extended into unsupported anti-aging use.
Hyperbaric oxygen therapy (HBOT) is the delivery of 100% oxygen at raised ambient pressure, typically 2–3 atmospheres, inside a sealed chamber. It belongs to the Gas, Oxidative & Pressure family, and within this atlas it plays a particular role: it is the positive-control anchor — conventional, established medicine whose real mechanism makes the whole evidence gradient legible. If you want to see what “a dosed physical mechanism with regulatory clearance and grade-A evidence” actually looks like, HBOT is the reference point.
The mechanism is well-characterised physiology, not analogy. Under pressure, far more oxygen dissolves directly into blood plasma (Henry's law), so oxygen reaches ischemic tissue that the haemoglobin-bound supply cannot adequately serve. That single lever — dissolved plasma O₂ delivered to oxygen-starved tissue — underwrites the downstream effects: support for wound healing, control of certain infections, and management of gas emboli and carbon-monoxide poisoning. Crucially, the dose is defined and quantifiable: pressure (in atmospheres), inspired oxygen fraction (FiO₂), and session time. This is what separates HBOT from “energy medicine” — a measurable input acting on a measurable target through known physiology.
HBOT earns a grade A within its 13 FDA-cleared indications. For those uses — the cleared list spanning conditions such as wound and tissue-injury indications, decompression illness, and carbon-monoxide poisoning — the physiology is established and the clinical basis is solid; in the US these uses are Medicare-covered. A 2021 overview of HBOT's applications, mechanisms, and approved indications (Medicina, 2021) summarises both the established indications and the variable quality of evidence across them; the off-label uses (autism, Alzheimer's, anti-aging) remain unsubstantiated. What the record does state firmly is the shape of the claim: grade A is bounded to the cleared indications and does not travel with the device into other uses. The honest failure mode is over-extension — the same pressure-and-oxygen apparatus marketed for autism, Alzheimer's, or general anti-aging, where the cleared-indication evidence simply does not reach. “Works for decompression illness” is not “works for ageing.”
HBOT sits in the Evidence-supported tier, and it is worth seeing why the three axes line up here rather than collapsing into one. Plausibility is high: the physiology is established, with a defined dose. Evidence grade is A — but only for the cleared indications. Tier follows the claim: for the cleared uses HBOT is Evidence-supported; for off-label anti-aging it would not be. Tier, grade, and plausibility are independent — a strong cleared indication does not license the broad ones, which is exactly the discipline this anchor is meant to demonstrate.
HBOT is broadly recognised across jurisdictions. In the US it is an FDA Class II device with 13 cleared indications and Medicare coverage; in the EU it is CE marked; in Russia and under China's NMPA it is hospital standard care; and in Australia the TGA treats it as standard care. As always in this atlas, these are market-access and standard-of-care facts for specific uses — a clearance attests to a defined indication, never to the general “rejuvenation” claims layered on top in the consumer market. Even for the genuine positive control, registration is not a warrant for off-label efficacy.
HBOT comes out of mainstream hyperbaric medicine, and on the atlas's lineage map it stands apart from the “frequency” and information-medicine threads entirely. It is the modality the others are measured against. What it shares with the fringe is only the marketing temptation — the move from a real, narrow, dosed effect to a sweeping whole-body promise.
Keep: conventional, dosed physiology for the cleared indications — real pressure-and-oxygen delivery with a defined dose and grade-A support. Set aside: the off-label extrapolations — autism, Alzheimer's, general anti-aging — which are unsubstantiated by the cleared-indication evidence. HBOT is genuine medicine; the discipline is in not letting that legitimacy be borrowed for claims it never earned.
Registration or clearance is a market-access fact, never proof of efficacy.
| US — FDA | Class II — 13 cleared indications; Medicare-covered. |
|---|---|
| EU — MDR | CE marked. |
| Russia | Hospital standard care. |
| China — NMPA | Hospital standard care. |
| Australia — TGA | Standard care. |